Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

Inclusion criteria

• Age 18 years or older.
• Patient for whom at least one mutation deemed of interest by the investigator has been identified.
• Patient with a malignant tumor at a locally advanced or metastatic stage, for whom a tissue tumor sample (via surgery, radiology, or endoscopy) is scheduled as part of their standard care.
• Tumor volume deemed sufficient by the physician to ensure an adequate amount of material for analysis by the pathologist and the transfer of a part of the tumor sample to the Laboratory of Translational Research in Oncology for the study.
• INR < 1.5; Platelets > 50,000/μL.
• Patient who has been informed of the study and has signed the informed consent form.
• Patient affiliated with a social security insurance.

Exclusion criteria

• Patient with multiple primary malignant tumors.
• Patient with a known HIV, Hepatitis C, or Hepatitis B infection.
• Patient on:

• Clopidogrel (hydrogensulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) with no possibility of suspension for 5 days,
• Low molecular weight heparin with no possibility of dose suspension before the procedure,
• Fondaparinux with no possibility of suspension,
• Abciximab with no possibility of suspension for 24 hours and aPTT < 50s and ACT < 150s,
• Eptifibatide or Tirofiban Hydrochloride Monohydrate or Argatroban with no possibility of suspension 4 hours before the procedure,
• Bivalirudin with no possibility of suspension 2-3 hours if CrCL >50 mL/min or 3-5 hours if CrCL <50 mL/min before the procedure,
• Dabigatran etexilate with no possibility of suspension 2-3 days if CrCL >50 mL/min or 3-5 days if CrCL <50 mL/min before the procedure.
• Patient considered vulnerable; vulnerable persons are defined in articles L1121-5 to L1121-8:

• Pregnant women, parturients, and breastfeeding mothers,
• Individuals deprived of their liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and individuals admitted to a healthcare or social facility for reasons other than research,
• Adults under legal protection or unable to express their consent.